focus -WSS

focus

author：knowledge 2025-10-06 06:38:00 - browse：176

Jamy Ard (left) and Robert Lustig (right) on the 2023 STAT Breakthrough Summit stage -- coverage from STAT — Obesity experts Jamy Ard (left) and Robert Lustig speak at a panel during the 2023 STAT Breakthrough Summit. Sarah Gonzalez for STAT

Amid rising demand for drugs like Wegovy, Ozempic, and Mounjaro that can lead to significant weight loss, some obesity experts are concerned about the drugs’ costs — both to patients’ finances and to their health.

Speaking at a panel on new obesity treatments at the STAT Breakthrough Summit in San Francisco on Thursday, one expert cited a large clinical trial for Wegovy that showed that about 40% of the weight participants lost was lean mass. Side effects like nausea, vomiting, and a possible link to rare cases of pancreatitis also still plague this newest class of drugs, which imitate the effects of a hormone called glucagon-like peptide 1 (GLP) that helps people feel full.

“That’s what starvation does. You lose equal amounts of muscle and fat,” said Robert Lustig, emeritus professor of pediatrics at the University of California, San Francisco. “If you’re a person 60 years old or over and you’re losing muscle, your risk of dying just went up exponentially. So we may be … robbing Peter to pay Paul.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： In Memoriam: Notable people who died in 2023
Next article： Adam's Biotech Scorecard: A closer look at Viking Therapeutics, PDS Biotech

leisure time

WSS

How Robert F. Kennedy Jr. distorted vaccine science

'Screen and refer' systems are hurting patients

Readout Newsletter: WuXi and Congress, Boundless Bio, etc.

Beware reading your test results before your doctor does

What affirmative action's end means to a medical student

Washington mulls new rules to avert another Change Healthcare

explore

focus

focus

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Penis shrinkage, a side effect of prostate cancer surgery, is temporary

United colonoscopy coverage change 'may cost lives,' doctors say

Readout Newsletter: Cardior, Regeneron, Nuvation, Dyne and more

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Skip the lead apron during X

State Dept. review finds Biden bears some blame for Afghanistan failures

Scientists boost immune system in aging mice by making it youthful

Duchenne breakthrough therapy leaves behind pioneering families

Donor acceptance rates hint at racial, gender bias in heart transplants: study

focus

AstraZeneca lung cancer study comes in below expectations

Abortion pill case raises question: who can sue the FDA?

Readout Newsletter: Cardior, Regeneron, Nuvation, Dyne and more

Prescription digital therapeutics are key to pharma’s future

Roche subsidiary Foundation Medicine opens new headquarters

Trump’s hydroxychloroquine hype: a risk to my treatment and to him

hotspot

focus

leisure time

focus